Utility of Adaptive Strategy and Adaptive Design for Biomarker-facilitated Patient Selection in Pharmacogenomic or Pharmacogenetic Clinical Development Program
In the early to late phases of conventional clinical trials, improvement of disease status at study baseline is the anchor of an effective treatment measured by therapeutic response. These population-based clinical trials do not formally account for disease-associated marker genotype or genome-assoc...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2008-12-01
|
| Series: | Journal of the Formosan Medical Association |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S092966460960005X |